$150M life sciences fund launches; Apricus names new CEO; Study: One in three seniors dies with Alzheimer's;

 @FierceBiotech: FDA staff review raises big questions about fate of Titan's Probuphine. More | Follow @FierceBiotech

@JohnCFierce: Biopharma's Top R&D Spenders - 2012. Special Report | Follow @JohnCFierce

@RyanMFierce: Fierce's top 5 feats in life sciences 'gamification'. Special Report | Follow @RyanMFierce

> Sir Chris Evans' £100 million life sciences fund for Wales has officially opened. It is using £50 million contributed by the Welsh government to encourage regional biotech development. Story

> Apricus Biosciences has named Richard Pascoe as its new CEO. Pascoe is the former CEO of Somaxon, which developed Silenor. Story

> OTC shares of InSite Vision ($INSV) surged this morning after the company reported positive data from a late stage study of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery. The penny stock is trading at 34 cents this morning. Release

> Protalix Biotherapeutics ($PLX) reports that Brazil has approved its ERT for Gaucher disease. Story

Medical Device News

 @FierceMedDev: FDA sticks Class I tag on Symbios' pump recall. Story | Follow @FierceMedDev

 @MarkHFierce: China's Dehaier Medical Systems will be one to watch in 2013 as it pursues govt. healthcare contracts at home. Story | Follow @MarkHFierce

 @DamianFierce: Third Rock Ventures-backed DC Devices hauled in another $10+ million for its heart failure device. More | Follow @DamianFierce

> NuVasive hit with FDA warning letter over spine device. More

> Johns Hopkins team takes step toward creating migraine blood Dx. Story

Pharma News

@FiercePharma: Have generics reached a saturation point? With 84% utilization, maybe. And specialty prices are soaring. Article | Follow @FiercePharma

@EricPFierce: 600,000 bottles of Glenmark's generic Singulair recalled for fishy smell. Recalls for odors not a rarity. Article | Follow @EricPFierce

> Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy. News

> Senator questions Pfizer's $2,000-a-month price on Xeljanz. Report

> Big Pharma drools after $25B market for pricey pet care. More

Biotech Research News

@EmilyMFierce: Not to alarm anyone, but new research suggests that the black plague may still be a threat today. Post | Follow @EmilyMFierce

> Protein points to hormone therapy-resistant prostate cancer. Report

> Stem cell treatment could accelerate diabetic wound healing. Story

> Mount Sinai gets $5M from NIH to study neurological voice condition. Item

> Scripps, Takeda renew pact to find CNS treatments. More

Pharma Manufacturing News

> Claris a buyout candidate as shortages remake injectables biz. Item

> AmerisourceBergen gets Walgreen, Boots biz. Story

> FDA now inspecting 'high risk' compounders. News

> Lilly warehouse thieves followed risk-assessment 'road map.' Report

And Finally… The Alzheimer's Association says that one in three elderly Americans now dies with the memory-wasting disease. Story

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.